Costs and Limitations

  • Developer organization name: Cyfluent
  • Certification Date: 22 May 2019
  • Product name: Cyfluent
  • Product version: Cyfluent 3.2
  • Unique certification number: 06262014-2424-8
  • This Complete EHR is 2014 Edition compliant and has been certified by an ONC-ACB in accordance with the applicable certification criteria adopted by the Secretary of Health and Human Services. This certification does not represent an endorsement by the U.S. Department of Health and Human Services.
  • EHR technology is certified to 170.315(b)(6) for Data Export to create a set of export summaries in real time base on a relative time and date. While the user can create a set of export summaries in real time based on relative time and date, this type of mass export is only allowed to be scheduled by support staff to reduce performance stress on the system.
  • Additional software used:
    –Change Healthcare. Providers must be signed up with Change Healthcare to access e-prescribing. The cost for basic e-prescribing is included in the monthly provider fee for the Cyfluent Professional Suite.  There is an additional fee for electronic prescribing of controlled substances.
    –Secure Exchange Solutions. Providers must also be signed up with a HISP for direct messaging which is also included in the monthly provider fee for the Cyfluent Professional Suite.
  • There is a Monthly Provider fee for Cyfluent Professional Suite which includes all costs needed for fully certified EHR.
  • Certification criterion or criteria to which the product has been certified:
    • 170.314(a)(1)  COMPUTERIZED PROVIDER ORDER ENTRY
    • 170.314(a)(2)  DRUG-DRUG, DRUG-ALLERGY INTERACTION CHECKS
    • 170.314(a)(3)  DEMOGRAPHICS
    • 170.314(a)(4)  VITAL SIGNS, BODY MASS INDEX, AND GROWTH CHARTS
    • 170.314(a)(5)  PROBLEM LIST
    • 170.314(a)(6)  MEDICATION LIST
    • 170.314(a)(7)  MEDICATION ALLERGY LIST
    • 170.314(a)(8)  CLINICAL DECISION SUPPORT
    • 170.314(a)(9)  ELECTRONIC NOTES
    • 170.314(a)(10)  DRUG-FORMULARY CHECKS
    • 170.314(a)(11)  SMOKING STATUS
    • 170.314(a)(12)  IMAGE RESULTS
    • 170.314(a)(13)  FAMILY HEALTH HISTORY
    • 170.314(a)(14)  PATIENT LIST CREATION
    • 170.314(a)(15)  PATIENT-SPECIFIC EDUCATION RESOURCES
    • 170.314(b)(1)  TRANSITIONS OF CARE – RECEIVE, DISPLAY, AND INCORPORATE TRANSITION OF CARE/REFERRAL SUMMARIES
    • 170.314(b)(2)  TRANSITIONS OF CARE – CREATE AND TRANSMIT TRANSITION OF CARE/REFERRAL SUMMARIES
    • 170.314(b)(3)  ELECTRONIC PRESCRIBING
    • 170.314(b)(4)  CLINICAL INFORMATION RECONCILIATION
    • 170.314(b)(5)  INCORPORATE LABORATORY TESTS AND VALUES/RESULTS
    • 170.314(b)(7)  DATA PORTABILITY
    • 170.314(c)(1)  CLINICAL QUALITY MEASURES – CAPTURE AND EXPORT
    • 170.314(c)(2)  CLINICAL QUALITY MEASURES – IMPORT AND CALCULATE
    • 170.314(c)(3)  CLINICAL QUALITY MEASURES – ELECTRONIC SUBMISSION
    • 170.314(d)(1)  AUTHENTICATION, ACCESS CONTROL, AND AUTHORIZATION
    • 170.314(d)(2)  AUDITABLE EVENTS AND TAMPER-RESISTANCE
    • 170.314(d)(3)  AUDIT REPORT(S)
    • 170.314(d)(4)  AMENDMENTS
    • 170.314(d)(5)  AUTOMATIC LOG-OFF
    • 170.314(d)(6)  EMERGENCY ACCESS
    • 170.314(d)(7)  END-USER DEVICE ENCRYPTION
    • 170.314(d)(8)  INTEGRITY
    • 170.314(e)(1)  VIEW, DOWNLOAD, AND TRANSMIT TO 3RD PARTY
    • 170.314(e)(2)  CLINICAL SUMMARY
    • 170.314(e)(3)  SECURE MESSAGING
    • 170.314(f)(1)  IMMUNIZATION INFORMATION
    • 170.314(f)(2)  TRANSMISSION TO IMMUNIZATION REGISTRIES
    • 170.314(f)(3)  TRANSMISSION TO PUBLIC HEALTH AGENCIES – SYNDROMIC SURVEILLANCE
    • 170.314(g)(2)  AUTOMATED MEASURE CALCULATION
    • 170.314(g)(3)  SAFETY-ENHANCED DESIGN
    • 170.314(g)(4)  QUALITY MANAGEMENT SYSTEM
    • CMS2  PREVENTIVE CARE AND SCREENING: SCREENING FOR CLINICAL DEPRESSION AND FOLLOW-UP PLAN
    • CMS22  PREVENTIVE CARE AND SCREENING: SCREENING FOR HIGH BLOOD PRESSURE AND FOLLOW-UP DOCUMENTED
    • CMS50  CLOSING THE REFERRAL LOOP: RECEIPT OF SPECIALIST REPORT
    • CMS52  HIV/AIDS: PNEUMOCYSTIS JIROVECI PNEUMONIA (PCP) PROPHYLAXIS
    • CMS56  FUNCTIONAL STATUS ASSESSMENT FOR HIP REPLACEMENT
    • CMS61  PREVENTIVE CARE AND SCREENING: CHOLESTEROL – FASTING LOW DENSITY LIPOPROTEIN (LDL-C) TEST PERFORMED
    • CMS62  HIV/AIDS: MEDICAL VISIT
    • CMS64  PREVENTIVE CARE AND SCREENING: RISK- STRATIFIED CHOLESTEROL – FASTING LOW DENSITY LIPOPROTEIN (LDL-C)
    • CMS65  HYPERTENSION: IMPROVEMENT IN BLOOD PRESSURE
    • CMS66  FUNCTIONAL STATUS ASSESSMENT FOR KNEE REPLACEMENT
    • CMS68  DOCUMENTATION OF CURRENT MEDICATIONS IN THE MEDICAL RECORD
    • CMS69  PREVENTIVE CARE AND SCREENING: BODY MASS INDEX (BMI) SCREENING AND FOLLOW-UP
    • CMS74  PRIMARY CARIES PREVENTION INTERVENTION AS OFFERED BY PRIMARY CARE PROVIDERS, INCLUDING DENTISTS
    • CMS75  CHILDREN WHO HAVE DENTAL DECAY OR CAVITIES
    • CMS77  HIV/AIDS: RNA CONTROL FOR PATIENTS WITH HIV
    • CMS82  MATERNAL DEPRESSION SCREENING
    • CMS90  FUNCTIONAL STATUS ASSESSMENT FOR COMPLEX CHRONIC CONDITIONS
    • CMS117  CHILDHOOD IMMUNIZATION STATUS
    • CMS122  DIABETES: HEMOGLOBIN A1C POOR CONTROL
    • CMS123  DIABETES: FOOT EXAM
    • CMS124  CERVICAL CANCER SCREENING
    • CMS125  BREAST CANCER SCREENING
    • CMS126  USE OF APPROPRIATE MEDICATIONS FOR ASTHMA
    • CMS127  PNEUMONIA VACCINATION STATUS FOR OLDER ADULTS
    • CMS128  ANTI-DEPRESSANT MEDICATION MANAGEMENT
    • CMS129  PROSTATE CANCER: AVOIDANCE OF OVERUSE OF BONE SCAN FOR STAGING LOW RISK PROSTATE CANCER PATIENTS
    • CMS130  COLORECTAL CANCER SCREENING
    • CMS131  DIABETES: EYE EXAM
    • CMS132  CATARACTS: COMPLICATIONS WITHIN 30 DAYS FOLLOWING CATARACT SURGERY REQUIRING ADDITIONAL SURGICAL PROCEDURES
    • CMS133  CATARACTS: 20/40 OR BETTER VISUAL ACUITY WITHIN 90 DAYS FOLLOWING CATARACT SURGERY
    • CMS134  DIABETES: URINE PROTEIN SCREENING
    • CMS135  HEART FAILURE (HF): ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITOR OR ANGIOTENSIN RECEPTOR BLOCKER (ARB) THERAPY FOR LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (LVSD)
    • CMS136  ADHD: FOLLOW-UP CARE FOR CHILDREN PRESCRIBED ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) MEDICATION
    • CMS137  INITIATION AND ENGAGEMENT OF ALCOHOL AND OTHER DRUG DEPENDENCE TREATMENT
    • CMS138  PREVENTIVE CARE AND SCREENING: TOBACCO USE: SCREENING AND CESSATION INTERVENTION
    • CMS139  SCREENING FOR FUTURE FALL RISK
    • CMS140  BREAST CANCER: HORMONAL THERAPY FOR STAGE IC-IIIC ESTROGEN RECEPTOR/PROGESTERONE RECEPTOR (ER/PR) POSITIVE BREAST CANCER
    • CMS141  COLON CANCER: CHEMOTHERAPY FOR AJCC STAGE III COLON CANCER PATIENTS
    • CMS142  DIABETIC RETINOPATHY: COMMUNICATION WITH THE PHYSICIAN MANAGING ONGOING DIABETES CARE
    • CMS143  PRIMARY OPEN ANGLE GLAUCOMA (POAG): OPTIC NERVE EVALUATION
    • CMS144  HEART FAILURE (HF): BETA-BLOCKER THERAPY FOR LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (LVSD)
    • CMS145  CORONARY ARTERY DISEASE (CAD): BETA-BLOCKER THERAPY- PRIOR MYOCARDIAL INFARCTION (MI) OR LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (LVEF <40%)
    • CMS146  APPROPRIATE TESTING FOR CHILDREN WITH PHARYNGITIS
    • CMS147  PREVENTATIVE CARE AND SCREENING: INFLUENZA IMMUNIZATION
    • CMS148  HEMOGLOBIN A1C TEST FOR PEDIATRIC PATIENTS
    • CMS149  DEMENTIA: COGNITIVE ASSESSMENT
    • CMS153  CHLAMYDIA SCREENING FOR WOMEN
    • CMS154  APPROPRIATE TREATMENT FOR CHILDREN WITH UPPER RESPIRATORY INFECTION (URI)
    • CMS155  WEIGHT ASSESSMENT AND COUNSELING FOR NUTRITION AND PHYSICAL ACTIVITY FOR CHILDREN AND ADOLESCENTS
    • CMS156  USE OF HIGH-RISK MEDICATIONS IN THE ELDERLY
    • CMS157  ONCOLOGY: MEDICAL AND RADIATION – PAIN INTENSITY QUANTIFIED
    • CMS158  PREGNANT WOMEN THAT HAD HBSAG TESTING
    • CMS159  DEPRESSION REMISSION AT TWELVE MONTHS
    • CMS160  DEPRESSION UTILIZATION OF THE PHQ-9 TOOL
    • CMS161  MAJOR DEPRESSIVE DISORDER (MDD): SUICIDE RISK ASSESSMENT
    • CMS163  DIABETES: LOW DENSITY LIPOPROTEIN (LDL) MANAGEMENT
    • CMS164  ISCHEMIC VASCULAR DISEASE (IVD): USE OF ASPIRIN OR ANOTHER ANTITHROMBOTIC
    • CMS165  CONTROLLING HIGH BLOOD PRESSURE
    • CMS166  USE OF IMAGING STUDIES FOR LOW BACK PAIN
    • CMS167  DIABETIC RETINOPATHY: DOCUMENTATION OF PRESENCE OR ABSENCE OF MACULAR EDEMA AND LEVEL OF SEVERITY OF RETINOPATHY
    • CMS169  BIPOLAR DISORDER AND MAJOR DEPRESSION: APPRAISAL FOR ALCOHOL OR CHEMICAL SUBSTANCE USE
    • CMS177  CHILD AND ADOLESCENT MAJOR DEPRESSIVE DISORDER: SUICIDE RISK ASSESSMENT
    • CMS179  ADE PREVENTION AND MONITORING: WARFARIN TIME IN THERAPEUTIC RANGE.
    • CMS182  ISCHEMIC VASCULAR DISEASE (IVD): COMPLETE LIPID PANEL AND LDL CONTROL